Ajanta Pharma Limited (NSE:AJANTPHARM)
India · Delayed Price · Currency is INR 2,695.20
-56.20 (-2.04%)
Aug 1, 2025, 3:29 PM IST
United States Steel Revenue
Ajanta Pharma had revenue of 13.03B INR in the quarter ending June 30, 2025, with 13.78% growth. This brings the company's revenue in the last twelve months to 48.06B, up 10.92% year-over-year. In the fiscal year ending March 31, 2025, Ajanta Pharma had annual revenue of 46.48B with 10.44% growth.
Revenue (ttm)
48.06B
Revenue Growth
+10.92%
P/S Ratio
7.00
Revenue / Employee
4.99M
Employees
9,628
Market Cap
336.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 46.48B | 4.39B | 10.44% |
| Mar 31, 2024 | 42.09B | 4.66B | 12.45% |
| Mar 31, 2023 | 37.43B | 4.02B | 12.02% |
| Mar 31, 2022 | 33.41B | 4.51B | 15.62% |
| Mar 31, 2021 | 28.90B | 3.02B | 11.66% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 274.80B |
| Apollo Hospitals Enterprise | 217.94B |
| Mankind Pharma | 122.07B |
| Zydus Lifesciences | 232.42B |
| Aurobindo Pharma | 317.24B |
| Fortis Healthcare | 77.86B |
Ajanta Pharma News
- 2 days ago - Top stocks to buy today: Stock recommendations for July 31, 2025 - check list - The Times of India
- 3 months ago - Ajanta Pharma Q4 Results: Net profit grows 11% YoY to Rs 225 crore, EBITDA Margin at 25% - Business Upturn
- 3 months ago - Stocks to buy today on brokerages’ call: IndiGo, Ajanta Pharma, TBO, HDFC Bank, Vodafone Idea among top picks – Check investment target - Business Upturn
- 3 months ago - Jefferies initiates Buy on Ajanta Pharma, sees 11% upside due to strong presence in branded generics markets - Business Upturn
- 3 months ago - Stocks to watch today: Interglobe Aviation, Ajanta Pharma, HDFC Bank, Vodafone Idea, Hindalco, TBO, L&T in focus on brokerage reports - Business Upturn
- 6 months ago - Ajanta Pharma Q3FY25 results: Revenue rises 4% YoY to Rs 1,146 crore, PAT Up 11% to Rs 233 crore - Business Upturn
- 8 months ago - Pharma Stocks: Cipla down nearly 2%, Ajanta Pharma down 1.45%, Abbott India up 1.27% - Business Upturn
- 9 months ago - Ajanta Pharma declares first interim dividend of ₹28 per share for FY25 - Business Upturn